Last updated: February 19, 2026
This analysis identifies key global suppliers of amiodarone hydrochloride API, focusing on production capacities, regulatory compliance, and market positioning.
Major API Manufacturers for Amiodarone Hydrochloride
| Company |
Location |
Production Capacity (kg/year) |
FDA/EMA Approvals |
Notable Certifications |
Market Focus |
| Zhejiang Hisun Pharmaceutical |
China |
Estimated 50,000+ |
British, US, EMA |
ISO 9001, ISO 14001, GMP-certified |
Global, especially US and Europe |
| ZCL Chemicals |
India |
Estimated 20,000+ |
USFDA, EMA |
GMP, ISO 9001 |
North America, Europe, Asia |
| Hubei Huahuan Pharmaceutical |
China |
10,000+ |
China GMP |
GMP certification |
Asia |
| VEM Healthcare |
India |
15,000+ |
USFDA, EU-GMP |
GMP certifications |
North America, Europe |
| Jiangsu Hengrui Medicine |
China |
Approximate 10,000 |
China GMP |
ISO certifications |
Asia |
Note: Exact production figures are proprietary but estimated based on industry reports and company disclosures.
Sources and Regulatory Status
- Manufacturers with US FDA approval: Zhejiang Hisun Pharmaceutical, ZCL Chemicals, VEM Healthcare.
- European registration: ZCL Chemicals and VEM Healthcare are compliant with EMA standards.
- Chinese GMP-certified producers: Zhejiang Hisun, Hubei Huahuan, Jiangsu Hengrui.
Supply Chain Considerations
-
Consolidation: Limited number of major producers supply bulk APIs.
-
Quality Assurance: Suppliers with GMP certification are preferred for regulatory compliance.
-
Pricing: Prices vary based on scale, certification, and supply agreement length.
-
Lead Time: Generally 3–6 months depending on order size and certification process.
Market Trends & Opportunities
- Rising demand in developing markets prompts increased capacity investments.
- Supply chain disruptions in China and India have prompted diversification efforts.
- API manufacturers expanding into contract manufacturing.
Regulatory & Quality Notes
- USFDA and EMA approval signifies adherence to strict manufacturing standards.
- Chinese suppliers adhering to GMP can supply for local and some international markets.
- International certification ensures compliance with pharmacopoeial standards (USP, BP, EP).
Key Takeaways
- China dominates API production with a handful of large-scale GMP-certified manufacturers.
- Indian firms ESG policies emphasize capacity growth and regulatory compliance.
- Limited high-quality suppliers influence pricing and supply stability.
- US and European approvals streamline import processes into respective markets.
- Supply chain diversification increasingly prioritized amid geopolitical and pandemic-related disruptions.
FAQs
Q1: What are the leading global suppliers of amiodarone hydrochloride API?
A1: Zhejiang Hisun Pharmaceutical (China), ZCL Chemicals (India), and VEM Healthcare (India).
Q2: Do all API suppliers for amiodarone hydrochloride have international regulatory approvals?
A2: No. Some Chinese manufacturers hold Chinese GMP certificates, while a subset has USFDA and EMA approvals.
Q3: How does regulatory status affect sourcing options?
A3: USFDA and EMA approval facilitates import into corresponding markets with fewer regulatory hurdles. Non-approved suppliers require additional validation.
Q4: Are there supply risks associated with a limited number of API producers?
A4: Yes. Supply disruptions from any major manufacturer can impact availability and pricing.
Q5: What trends are influencing the API market for amiodarone hydrochloride?
A5: Capacity expansion in emerging markets, supply chain diversification efforts, and increasing regulatory compliance requirements.
References
- Industry reports on global API manufacturing capacities.
- Company disclosures and certifications.
- Regulatory agency guidelines (US FDA, EMA).
- Market analysis documents from pharmaceutical trade organizations.
- Public FDA drug master files and European Union registration dossiers.
